EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology- Canada

doi 10.3747//co.19.955

Full Text

Abstract

Available in

Categories

Date

February 1, 2012

Authors

Publisher

MultiMed Inc.

Related search

EGFR Tyrosine Kinase Inhibitors in Lung Cancer: Make No Assumptions

Current Oncology

English

Tyrosine Kinase Inhibitors in Lung Cancer

Hematology/Oncology Clinics of North America

Tagalog

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy

English

Novel Third-Generation EGFR Tyrosine Kinase Inhibitors and Strategies to Overcome Therapeutic Resistance in Lung Cancer

Cancer Research

Cancer Research

English

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Oncology in Clinical Practice

English

Compound EGFR Mutations and Response to EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology

Respiratory Medicine

English

P1.01-19 Efficacy of Tyrosine Kinase Inhibitors in EGFR Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastases

Journal of Thoracic Oncology

Respiratory Medicine

English

Impressive Response to Tyrosine Kinase Inhibitors in a Patient With Respiratory Failure for EGFR -Mutated Metastatic Lung Cancer

Journal of Thoracic Oncology

Respiratory Medicine

English

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology

Respiratory Medicine

English